DeCode Enters Bankruptcy, Looks To Sell Assets To Its Former VCs
This article was originally published in The Pink Sheet Daily
Saddled by $314 million in debt, the Icelandic firm files for Chapter 11 protection.
You may also be interested in...
Personalized medicine firm digs its way out of suffocating debt, hoping mystery investors will help the company survive 2009.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.